Clinical Research Directory
Browse clinical research sites, groups, and studies.
Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer
Sponsor: M.D. Anderson Cancer Center
Summary
This phase II/III trial studies an open labeled placebo to see how well it works compared with waitlist control in reducing cancer related fatigue in patients with cancer that has spread to other places in the body. A placebo is not a drug and is not designed to treat any disease or illness. Recent studies have found that cancer related fatigue symptoms in cancer survivors are improved with open labeled placebo (that is, patients know they are taking a placebo). It is not yet known how well an open labeled placebo works when compared with waitlist control in reducing cancer related fatigue.
Official title: Open Labeled Placebo for Treatment of Cancer Related Fatigue in Patients With Advanced Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2019-03-30
Completion Date
2026-12-31
Last Updated
2026-02-19
Healthy Volunteers
No
Conditions
Interventions
Placebo Administration
Given open labeled placebo PO
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Waiting List
Assigned to a waiting list
Locations (1)
M D Anderson Cancer Center
Houston, Texas, United States